<DOC>
	<DOCNO>NCT00662714</DOCNO>
	<brief_summary>Is oral therapy Repaglinide equivalent insulin therapy three daily injection respect blood glucose control , weight pulmonary function 2 year patient cystic fibrosis secondary diabetes mellitus ? That question examine phase III trial .</brief_summary>
	<brief_title>Early Diagnosis Diabetes Mellitus Patients With Cystic Fibrosis</brief_title>
	<detailed_description>Diabetes mellitus may present patient cystic fibrosis ( mucoviscidosis ) start second decade life . The prevalence increase rapidly increase age . As life-expectancy increase CF , CF-related diabetes diagnose frequently future . Negative consequence secondary diabetes cystic fibrosis include : - Catabolic metabolism - Weight loss - More frequent / severe infection - Deterioration pulmonary function - Reduced life-expectancy - Diabetic micro vascular complication ( retinopathy , nephropathy , neuropathy ) Up date , data available answer question , whether secondary diabetes CF always treat insulin therapy . Several centre report successful management CF-related diabetes use oral anti-diabetic drug least year . Oral therapy would less invasive patient group highly traumatise demand therapy ( multiple drug include antibiotic , pancreas enzyme , bronchodilator , mucolysis , addition physiotherapy , regular inpatient iv-antibiotic therapy etc , finally lung transplant subgroup patient ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<criteria>Inclusion Criteria Screening : Diagnosed cystic fibrosis Age 10 year old Inclusion Criteria therapeutic part study : Newly diagnose Diabetes mellitus screen Exclusion Criteria Screening : Diabetic ketoacidosis ( blood glucose &gt; 350 mg/dl arterial pH &lt; 7.25 ) Already treat Diabetes mellitus oral antidiabetic medication insulin Exclusion Criteria therapeutic part study : Systemic steroid therapy last 3 month Transplantation ( status post TX wait list TX ) Beginning pulmonary insufficiency , FEV1 &lt; 35 % pulmonary function test stable condition Pregnancy Already diagnose treat diabetes mellitus Patients diabetic ketoacidosis ( blood glucose &gt; 350 mg/dl arterial pH &lt; 7.25 ) without diabetic coma Severe liver insufficiency ( chronic hepatitis B , AST ALT twice upper limit normal , Quick 's value &lt; 70 % contraindication use Repaglinide ) Treatment indispensable important drug contraindicates Repaglinide PEG/ gastric tube/ total parenteral alimentation 4 week study CFpatients type 1 diabetes Not patient 's consent randomisation therapeutic trial Participation medical trial</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>